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Natural killer (NK) cells are large granular lymphocytes
that play a critical role in anti-cancer mechanisms. These
effector cells mediate antibody-dependent cellular cyto-
toxicity (ADCC) and produce IFN-g in response to
antibody-coated targets. The monoclonal antibody cetuxi-
mab targets the epidermal growth factor receptor (EGFR),
which is over expressed in the majority of pancreatic
cancers, but fails to effectively block MAP kinase activity
when KRAS is concurrently mutated. Interleukin-21
(IL-21) is an immunomodulatory cytokine that stimulates
the anti-tumor response of NK cells. We hypothesized
that IL-21 treatment of NK cells would enhance their
response to cetuximab-coated EGFR-positive pancreatic
tumor cells, regardless of KRAS mutational status and
thereby generate an effective anti-tumor response. Expres-
sion of EGFR was measured on six human pancreatic can-
cer cell lines. All six cell lines showed >85% expression of
EGFR by flow cytometry, which was confirmed by immu-
noblot assay. NK cells from normal healthy donors and
pancreatic cancer patients were treated overnight with
IL-21 (10 ng/ml) and tested for their ability to lyse cetuxi-
mab-coated tumor cells in a standard 4-hour 51Cr release
assay. NK cell killing of cetuximab-coated wild-type and
mutant KRAS cell lines was significantly higher following
NK cell IL-21 treatment, as compared to controls (p <
0.001). In response to cetuximab-coated pancreatic tumor
cells, IL-21 treated NK cells secreted significantly higher
levels of IFN-g (p < 0.001), released higher levels of the
chemokines IL-8, MIP1a/b, and RANTES (p < 0.001),
induced greater chemotaxis of T cells (p < 0.01), and
enhanced NK cell signal transduction via activation of
ERK and STAT1. Treatment of mice bearing subcuta-
neous EGFR-positive/KRAS mutant pancreatic tumor
xenographs with mIL-21 and cetuximab led to significant
inhibition of tumor growth as compared to control condi-
tions (p < 0.05). This result was confirmed in a second
intraperitoneal model of pancreatic cancer. Treatment of
tumor bearing mice with gemcitabine and cetuximab in
combination led to only a modest reduction in tumor bur-
den in vivo (as is seen in humans), but this effect was
markedly enhanced by the addition of IL-21 (p < 0.05).
Overall, this data suggests that cetuximab treatment in
combination with IL-21 can greatly enhance NK cell effec-
tor functions and mediate a significant anti-tumor
response in EGFR-positive pancreatic cancers in the
presence of mutated KRAS.
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